

July 31, 2025

To  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
25<sup>th</sup> Floor, Dalal Street,  
Mumbai – 400 001

**The National Stock Exchange of India Ltd**  
Exchange Plaza,  
Bandra Kurla Complex  
Bandra (E), Mumbai – 400 001

**Scrip Code: 524558**

**Scrip Code: NEULANDLAB; Series: EQ**

Dear Sir/Madam,

**Sub: Update on Outcome of Board meeting and Change in Directorate disclosures regarding appointment of additional director - Rectification of typo error**

**Ref: Our letter dated July 31, 2025**

We refer to our cover letter dated July 31, 2025, regarding the outcome of the Board meeting, which includes disclosures on approval of (i) the unaudited financial results and (ii) the appointment of a director.

Please note that there was a typographical error in the subject line under Disclosure B. It should be read as Appointment, instead of Reappointment, as under:

**B. Appointment of Dr. Ravi Shankar Gopinath (DIN: 00803847) as an Additional Director of the Company**

You may note that there are no other changes in the disclosures, except the above.

We regret the inconvenience caused in this regard.

This is for your information and records.

Yours sincerely,  
For **Neuland Laboratories Limited**

**Sarada Bhamidipati**  
**Company Secretary**

*Encl: As above*